3 Israeli Startups - Boomerang, NiNiSpeech & AerialGuard - Chosen to Represent Israel at Shengjing Global Innovation Awards 2016 in Beijing, Competing Against Startups From U.S., Europe, and China for Prizes Worth $1.5 Million - Seite 2

Israeli startup DiACardio, which is revolutionizing heart ultrasound, was named the winner of the 1st annual Global Innovation Awards during last year's finals in Beijing.

"We put a lot of emphasis on choosing companies with solid global potential which understand market trends on a worldwide basis," said Yoav Tzruya, JVP Partner. "There is a lot of deep technology in the Global Innovation Awards competition this year and this is a true testament to the Israeli tech ecosystem."

"This year, we are pleased to see that there are a wide variety of companies in the competition, including those with specific applicability to the Chinese market," said Sherrie Wang, Senior Partner, Shengjing. "DiACardio already has its first Chinese customer. We have already invested over $60 million in Israel."

Also participating were: Xueling Cao, Director at Shengjing; Kobi Rozengarten, Raffi Kesten and Gadi Tirosh, Managing Partners at JVP; Fiona Darmon, Partner & COO at JVP; Hanan Haviv, Partner at HFN; Yoram Teitz, Managing Partner at EY; and Rakefet Sudri, Head of Sales at PR Newswire Israel. Participating judges included: Steven Katz, Principal Investor at EMC Ventures; Amir Pinchas, Head of Operations & Portfolio at Microsoft Accelerator; Ari Aslan, Partner at EY; Yossi Vinitski, Head of High Tech at Bank Hapoalim; Merav Rotem-Naaman, Head of Nautilus by Aol; Ronen Hausirer, Partner, Technology Licensing Group of the Hi-Tech Department at HFN; Yoav Kantor, Key Account Manager at PR Newswire Israel.

The Three Finalists that Will Represent Israel in the Beijing Finals:  

Boomerang is developing a genetic device for cancer therapy based on a concept of a logic AND gate: the activation of our CRISPR-based system is dependent on the existence of two cancer-specific markers inside the cell, promising an extremely specific treatment. Using advanced gene editing tools, our system is able to effectively eliminate cancer cells by activating suicide genes. Moreover, our system can be potentially designed according to the genetics of each patient's tumor, paving the way to personalized medicine.